Publication Plan. Within [***] ([***]) days after the Effective Date, each Party shall designate an individual to serve as that Party’s “Publication Manager.” The Parties shall, through the Publication Managers, cooperate in good faith and develop and execute a coordinated publication plan in or for the Territory that will include strategy, budget and policies for the publication activities related to the Products. The publication plan will also cover intended timing, venue, media, review, authors and other relevant considerations for each publication. The publication plan will be included in the Commercialization Plan for approval by the JSC. A Party may change its Publication Manager at any time upon written notice to the other Party.
Publication Plan. Subject to the terms of Section 12.7.2 (Publication Guidelines), each Party shall have the right to publish summaries of results of all Clinical Trials conducted by or on behalf of such Party during the Term with respect to a TAK-385 Licensed Product; provided, however, that the other Party shall have the right to review all such proposed publications prior to submission of such publication, and the proposing Party shall deliver to the other Party a copy of the proposed written publication at least [***] days prior to submission for publication, in order to review the Clinical Trial results and any and all such data which are the subject of such proposed publication in order to prepare any necessary Patent Office filings. The Parties shall discuss and reasonably cooperate in order to facilitate and ensure publication under this Section 12.7.1 (Publication Plan) of any such summaries of Clinical Trial data and results as required under Applicable Law on the Clinical Trial registry of each respective Party.
Publication Plan. Aim: The aim of the Publications Plan of the ROAMER project is to maximise the scientific impact of the project by facilitating the production of high quality scientific papers and reports in a timely manner and by disseminating them in the most efficient way and assuring the appropriate acknowledgement of authorship, collaboration and financial support.
Publication Plan. There is scope to combine and expand the above-outlined literature reviews into an impactful review article. There is variation in the existence and extent of recent review articles that cover costs and damages amongst the five focus pests of the PurPest project. However, together these species comprise five representative case studies of EU priority pests that span different taxonomies, sectoral impacts, and stages of the invasion process. We therefore plan to construct a Europe-focused review article covering studies and assessments on the existing and potential costs associated with the damage caused by, and the control of, these five plant pests. The aim of reviewing this information is to address wider discussion points on the importance and implications of accurately investigating and quantifying economic consequences of priority pests, the extent to which this is achieved and harmonised amongst priority pests, and the interdisciplinary approaches required to more effectively study this crucial issue.
Publication Plan. All Publications shall first be provided to BMS for review and comment at least thirty (30) days prior to submission for publication or other disclosure (including any abstract submission or patent application). At BMS’ request, Institution shall delete from the proposed Publication all specified BMS Confidential Information (except for relevant BMS Data). If BMS determines that such proposed Publication contains or may contain patentable subject matter, Institution shall delay such presentation, publication or other disclosure to allow sufficient time for the drafting and filing of a patent application directed to such subject matter. “
Publication Plan. Each Party recognizes that the presentations and publication of papers or manuscripts regarding results of, and other information regarding, activities under this Agreement, including manuscripts, oral presentations, posters and abstracts (collectively, “Publications”), may be beneficial to both Parties; provided such Publications do not disclose Confidential Information of the other Party and are made in a coordinated manner between the Parties. Accordingly, each Party shall not make any Publications except in a manner consistent with the publication plans with respect to the Products in the Field (the “Presentation and Publication Plans”) and the terms of this Section 12.6.1. The initial version of the Presentation and Publication Plan with respect to the WH Product(s) in the WH Field is set out in [***], and the initial version of the Presentation and Publication Plan with respect to Oncology Product(s) in the Oncology Field is set out in [***]. The applicable IPOC and JMDRC shall periodically review each Presentation and Publication Plan and propose and approve any appropriate amendments with respect thereto.
Publication Plan. Mpex shall not publish any Information arising from performance of the Development Plan without the prior written consent of Axcan.
Publication Plan. Posting Research Protocol Prior to conducting the Research, Institution shall publish the Research Protocol on a publicly-available website. Institution agrees that BMS is free to use a cross-reference to the published Research Protocol and/or webpage on which it is posted (e.g., BMS is free to publish on its website a hyperlink to same).
Publication Plan. Takeda shall have the right to publish summaries of, and papers and presentations regarding data and results of all Clinical Trials conducted by or on behalf of Takeda with respect to the Vaccine in the Takeda Territory after the Effective Date; provided, however, that Novavax shall have the right to review all proposed publications [***] prior to submission of such publication. Novavax shall have the right to review, comment on and approve each such proposed publication or presentation for accuracy and to ascertain whether such proposed publication or presentation includes any disclosure of Novavax’ Confidential Information. Novavax shall have the right to request Takeda in writing to remove any of its Confidential Information prior to submission for publication or presentation. Takeda shall redact or otherwise modify the proposed publication or presentation to remove any such Confidential Information of Novavax pursuant to Novavax’ written request. For clarity, publications and presentations referenced in this Section 12.9 do not include Regulatory Filings. The Parties shall discuss and reasonably cooperate in order for Takeda to publish summaries of Clinical Trials data and results as required under Applicable Law on the Clinical Trial registry.
Publication Plan. The Parties may, through the joint medical committee, establish a publication plan setting forth the strategy, procedures, and rules governing academic, scientific, medical, and other publications and presentations for the Compound and Products. If any such plan is established, the Parties shall comply with such plan.
